Keywords: astrazeneca, sales, rise, nexium, doing, well, says
AstraZeneca sales rise 8%, Nexium doing well
Article | 26 July 2001
AstraZeneca says that second-quarter 2001 turnover rose 8% to $4.10billion, while operating profits declined 4% to $996 million and pretax profits fell 2% to $1.02 billion. ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
